Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander Tenenbaum

Showing results (91-100 of 116) with videos related to

Pageof 12
Sort By:
The American Journal of Cardiology|June 21, 2006
Interleukin-6 and the risk of future cardiovascular events in patients with angina pectoris and/or healed myocardial infarctionEnrique Z Fisman, Michal Benderly, Ricardo J Esper, et al.
Journal of Hypertension|April 13, 2004
Coronary calcium by spiral computed tomography predicts cardiovascular events in high-risk hypertensive patientsJoseph Shemesh, Nira Morag-Koren, Uri Goldbourt, et al.
Cardiovascular Diabetology|May 24, 2017
The addition of vildagliptin to metformin prevents the elevation of interleukin 1ß in patients with type 2 diabetes and coronary artery disease: a prospective, randomized, open-label studyArwa Younis, Dana Eskenazi, Ronen Goldkorn, et al.
Stroke|June 3, 2006
C-reactive protein as a predictor of incident ischemic stroke among patients with preexisting cardiovascular diseaseDavid Tanne, Michal Benderly, Uri Goldbourt, et al.
European Heart Journal|May 6, 2005
Effect of bezafibrate on incidence of type 2 diabetes mellitus in obese patientsAlexander Tenenbaum, Michael Motro, Enrique Z Fisman, et al.
Circulation|May 5, 2004
Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery diseaseAlexander Tenenbaum, Michael Motro, Enrique Z Fisman, et al.
Cardiovascular Diabetology|September 19, 2019
Metformin therapy in patients with diabetes mellitus is associated with a reduced risk of vasculopathy and cardiovascular mortality after heart transplantationEilon Ram, Jacob Lavee, Alexander Tenenbaum, et al.
The American Journal of Medicine|April 12, 2003
Functional class in patients with heart failure is associated with the development of diabetesAlexander Tenenbaum, Michael Motro, Enrique Z Fisman, et al.
Cardiovascular Diabetology|January 29, 2009
Long-term effects of peroxisome proliferator-activated receptor ligand bezafibrate on N-terminal pro-B type natriuretic peptide in patients with advanced functional capacity impairmentKoichi Node, Teruo Inoue, Valentin Boyko, et al.
International Journal of Cardiology|March 31, 2010
Long-term changes in serum cholesterol level does not influence the progression of coronary calcificationAlexander Tenenbaum, Joseph Shemesh, Nira Koren-Morag, et al.
Pageof 12

Showing results (91-100 of 116) with videos related to

Sort By:
Pageof 12
The American Journal of Cardiology|June 21, 2006
Interleukin-6 and the risk of future cardiovascular events in patients with angina pectoris and/or healed myocardial infarctionEnrique Z Fisman, Michal Benderly, Ricardo J Esper, et al.
Journal of Hypertension|April 13, 2004
Coronary calcium by spiral computed tomography predicts cardiovascular events in high-risk hypertensive patientsJoseph Shemesh, Nira Morag-Koren, Uri Goldbourt, et al.
Cardiovascular Diabetology|May 24, 2017
The addition of vildagliptin to metformin prevents the elevation of interleukin 1ß in patients with type 2 diabetes and coronary artery disease: a prospective, randomized, open-label studyArwa Younis, Dana Eskenazi, Ronen Goldkorn, et al.
Stroke|June 3, 2006
C-reactive protein as a predictor of incident ischemic stroke among patients with preexisting cardiovascular diseaseDavid Tanne, Michal Benderly, Uri Goldbourt, et al.
European Heart Journal|May 6, 2005
Effect of bezafibrate on incidence of type 2 diabetes mellitus in obese patientsAlexander Tenenbaum, Michael Motro, Enrique Z Fisman, et al.
Circulation|May 5, 2004
Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery diseaseAlexander Tenenbaum, Michael Motro, Enrique Z Fisman, et al.
Cardiovascular Diabetology|September 19, 2019
Metformin therapy in patients with diabetes mellitus is associated with a reduced risk of vasculopathy and cardiovascular mortality after heart transplantationEilon Ram, Jacob Lavee, Alexander Tenenbaum, et al.
The American Journal of Medicine|April 12, 2003
Functional class in patients with heart failure is associated with the development of diabetesAlexander Tenenbaum, Michael Motro, Enrique Z Fisman, et al.
Cardiovascular Diabetology|January 29, 2009
Long-term effects of peroxisome proliferator-activated receptor ligand bezafibrate on N-terminal pro-B type natriuretic peptide in patients with advanced functional capacity impairmentKoichi Node, Teruo Inoue, Valentin Boyko, et al.
International Journal of Cardiology|March 31, 2010
Long-term changes in serum cholesterol level does not influence the progression of coronary calcificationAlexander Tenenbaum, Joseph Shemesh, Nira Koren-Morag, et al.
Pageof 12